New drug for advanced pancreatic cancer after other treatments stop working
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests a new drug for people with advanced pancreatic cancer that has grown despite at least one prior chemotherapy. The goal is to see if this drug can shrink tumors or slow the cancer, potentially giving patients more time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with pancreatic ductal adenocarcinoma that cannot be removed by surgery.
- Your cancer has gotten worse during or after at least one prior chemotherapy treatment, such as FOLFIRINOX, gemcitabine, capecitabine, or erlotinib.
- You are well enough to care for yourself (performance status 0 or 1) and doctors expect you to live at least 12 more weeks.
- You have at least one measurable tumor that can be seen on a scan.
- You have not received any prior immunotherapy (like checkpoint inhibitors).
- You do not have uncontrolled fluid build-up in your belly, chest, or around the heart, and no untreated brain metastases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug (MRG004A) for advanced pancreatic cancer that has not responded to earlier treatments. The drug is given together with best supportive care (treatments to manage symptoms), and compared to a placebo (a dummy treatment) with best supportive care. The goal is to see if the new drug can slow down the cancer and help you live longer.
This trial tests a new kind of immunotherapy for pancreatic cancer that has not been removed by surgery or has spread. It aims to see if the treatment can help shrink or control the cancer, and you may be eligible whether you have had previous chemotherapy or not.
This trial tests a new targeted drug (LM-302) combined with a standard chemotherapy drug (gemcitabine) for people with advanced pancreatic cancer that has progressed after initial treatment. The goal is to see if this combination can slow down or shrink the cancer.
This trial tests a new drug called LM-108 combined with chemotherapy for people with advanced pancreatic cancer that hasn't been treated before. The goal is to see if it's safe and may help shrink tumors or stop them from growing.
This trial tests a combination of chemotherapy (NALIRI-XELOX) plus a newer immunotherapy drug (AK104) as a first treatment for people with advanced pancreatic cancer that hasn't been treated yet. The goal is to see if this combination works better than standard treatments.
This trial tests a combination of three chemotherapy drugs (mFOLFIRINOX) along with anlotinib (a targeted therapy) and sintilimab (an immunotherapy) for people with advanced pancreatic cancer who have not had prior treatment. The goal is to see if this combination can help shrink tumors or slow the disease.
Hear when a new Pancreas Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.